Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriasis. Immunopathology and immunomodulation.

A B Gottlieb1

  • 1Clinical Research Center, University of Medicine and Dentistry New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. gottliab@umdnj.edu

Dermatologic Clinics
|November 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature review.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

The British journal of dermatology·2021
Same author

Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).

The British journal of dermatology·2020
Same author

Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.

The British journal of dermatology·2020
Same author

Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.

The British journal of dermatology·2019
Same author

Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.

The British journal of dermatology·2019
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
Same journal

Microcoring.

Dermatologic clinics·2026
See all related articles

New biologic therapies are emerging for moderate to severe plaque psoriasis. These immunomodulators act as probes to uncover key targets in psoriasis development.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Moderate to severe plaque psoriasis requires advanced treatment options.

Purpose of the Study:

  • To discuss biologics in development for plaque psoriasis.
  • To highlight the role of immunomodulators in identifying pathogenic targets.

Main Methods:

  • Review of current and emerging biologic therapies.
  • Analysis of immunomodulators as tools for target identification.

Main Results:

  • Several biologics are in development for psoriasis.
  • Immunomodulators are crucial for understanding disease mechanisms.

Related Experiment Videos

Conclusions:

  • Biologics offer promising treatment avenues for psoriasis.
  • Continued research using immunomodulators will advance psoriasis pathogenesis understanding.